Conformal Radiotherapy and Intensity-modulated Radiotherapy: Clinical Data

• Published in: Acta oncologica 2000, Vol.39 (5), p.555-567
• Main Authors: TUBIANA, Maurice, ESCHWEGE, Francois
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Dose Fractionation, Radiation; Forecasting; Head and Neck Neoplasms - radiotherapy; Humans; Male; Medical sciences; Prostatic Neoplasms - radiotherapy; Radiation therapy and radiosensitizing agent; Radiotherapy, Conformal - methods; Survival Analysis; Treatment Outcome; Treatment with physical agents; Treatment. General aspects; Tumors
• ISSN: 0284-186X; 1651-226X
• DOI: 10.1080/028418600750013249

Conformal radiotherapy (CRT) is based on three hypotheses: (i) a higher rate of local control can improve the survival rate; (ii) dose escalation can increase tumor control; and (iii) CRT allows the delivery of higher doses by decreasing the incidence of late effects. These postulates are now supported by several data. Three-dimensional conformal radiotherapy (3D-CRT) has markedly progressed since its introduction two decades ago. However, there are situations for which 3D-CRT cannot produce a satisfactory treatment plan because of complex target volume shapes or the close proximity of sensitive normal tissues. This is why intensity-modulated radiation therapy (IMRT) was introduced. Its aim is to overcome the limitations of 3D-CRT by adding modulators of beam intensity to beam shaping. IMRT can achieve nearly any dose distribution; however, the role of the planner remains crucial. CRT has been investigated mainly for prostate cancers and head and neck cancers. By and large, the clinical data, although still limited, seem to confirm the advantages of this type of radiotherapy. Dose escalation in prostate cancers improves the local control rate without increasing late effects and for this cancer site IMRT appears to be a significant advance over conventional 3D-CRT. In head and neck cancers the clinical data are still scarce but encouraging. CRT should be investigated in breast cancers with the aim of reducing the incidence of late effects. The available data underline the great potential for major progress in 3D-CRT and IMRT. The techniques are still costly and time consuming, nevertheless they merit investigation since their cost should decrease. Efforts should be concentrated on the specification of robust optimization criteria, taking into account clinical and radiobiological data.